Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism.

In the quantitative studies of presynaptic dopamine metabolism by PET with 6-[18F]fluoro-L-dopa (6-[18F]FDOPA), metabolic analysis in the plasma is required to determine the precise input function because of susceptibility of the compound to peripheral metabolism. In this study, we prepared 6-[18F]-fluoro-O-pivaloyl-L-dopa (6-[18F]FPDOPA) as a prodrug of 6-[18F]FDOPA, and evaluated its potential as a PET tracer in mice. If the 6-[18F]FPDOPA is stable peripherally and is hydrolyzed to 6-[18F]FDOPA in the brain tissues, disadvantage of the 6-[18F]FDOPA will be overcome. Compared with the 6-[18F]FDOPA, the initial brain uptake of the 6-[18F]FPDOPA was lower; however, the uptake in the latter become comparable, and the uptake ratios of striatum to other reference regions were larger. Medication of mice with inhibitors of aromatic amino acid decarboxylase and catechol-O-methyl transferase greatly enhanced the striatal uptake of the two compounds. The reduced brain uptake of the compounds by L-phenylalanine-loading suggested transport through the blood-brain barrier by the neutral amino acid transporter. HPLC analysis showed the presence of 6-[18F]FPDOPA, 6-[18F]FDOPA and 6-[18F]fluorodopamine in the striatum; however, 6-[18F]fluoro-3-O-methyl-L-dopa was a predominate metabolite in the brain and plasma as in the case of [18F]FDOPA. Results suggested that 6-[18F]FPDOPA had characteristics as a prodrug of 6-[18F]FDOPA; however, the compound was also labile to metabolic alteration in vivo.

[1]  E. Mcgeer,et al.  The Metabolism of [18F]6‐Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Hooded Rat , 1987, Journal of neurochemistry.

[2]  C Nahmias,et al.  Cerebral Metabolism of 6–[18F]Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Primate , 1987, Journal of neurochemistry.

[3]  M. Senda,et al.  HPLC using physiological saline for the quality control of radiopharmaceuticals used in PET studies , 1993 .

[4]  M. da Prada,et al.  Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. , 1990, Advances in neurology.

[5]  T. Aigner,et al.  Distribution and Kinetics of 3-O-Methyl-6-[18F]fluoro-L-DOPA in the Rhesus Monkey Brain , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  C. Nahmias,et al.  Metabolites of 6-[18F]fluoro-L-dopa in human blood. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  M. Adam,et al.  Synthesis and separation of 3-O-Methyl-2- and 6-[18F]-fluorodopa , 1992 .

[8]  O. DeJesus,et al.  [18F]fluoro-beta-fluoromethylene-m-tyrosine analogs, potential PET agents for presynaptic dopamine terminals: synthesis and spectroscopic characterization. , 1992, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[9]  J. Rinne,et al.  [18F]‐6‐Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR‐462) , 1992, Neurology.

[10]  Y. Sawasaki,et al.  A new potential prodrug to improve the duration of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine. , 1989, Journal of pharmaceutical sciences.

[11]  Y. Nemerson,et al.  The esterase activity of coagulation factor VII. Evidence for intrinsic activity of the zymogen. , 1978, The Journal of biological chemistry.

[12]  A. Hisaka,et al.  Hydrolysis and acyl migration of a catechol monoester of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine. , 1990, Journal of pharmaceutical sciences.

[13]  A. Hisaka,et al.  Absorption of a novel prodrug of L-dopa, L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine (NB-355). In vitro and in situ studies. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[14]  S. Iversen,et al.  NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys. , 1989, Clinical neuropharmacology.

[15]  G. Sawle,et al.  The effect of entacapone (OR‐611) on brain [18F]‐6‐L‐fluorodopa metabolism , 1994, Neurology.

[16]  T. Aigner,et al.  New rapid analysis method demonstrates differences in 6-[18F] fluoro-L-dopa plasma input curves with and without carbidopa and in hemi-MPTP lesioned monkeys. , 1991, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[17]  B. Pate,et al.  Routine determination of [18F]-L-6-fluorodopa and its metabolites in blood plasma is essential for accurate positron emission tomography studies. , 1992, Life sciences.

[18]  G. Antoni,et al.  Striatal kinetics of [11C]‐(+)‐nomifensine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease measured with positron emission tomography , 1990, Acta neurologica Scandinavica.

[19]  M. Senda,et al.  Electrophilic synthesis of 6-[18F]fluoro-L-DOPA : use of 4-O-pivaloyl-L-DOPA as a suitable precursor for routine production , 1993 .

[20]  J C Mazziotta,et al.  The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  A. Gjedde,et al.  Pharmacokinetics of Plasma 6-[18F]Fluoro-l-3,4-Dihydroxyphenylalanine ([18F]FDOPA) in Humans , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  J. Barrio,et al.  Synthesis of 6-[18F] and 4-[18F]fluoro-L-m-tyrosines via regioselective radiofluorodestannylation. , 1993, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[23]  K. Ishiwata,et al.  Selective 2-[18F]fluorodopa uptake for melanogenesis in murine metastatic melanomas. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  M. Häusser,et al.  Kinetics of in vitro decarboxylation and the in vivo metabolism of 2-18F- and 6-18F-fluorodopa in the hooded rat. , 1988, Biochemical pharmacology.

[25]  O. DeJesus,et al.  Synthesis of radiofluorinated analogs of m-tyrosine as potential L-dopa tracers via direct reaction with acetylhypofluorite. , 1990, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.